Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: zolmitriptan

« Back to Dashboard

Summary for Generic Name: zolmitriptan

Drug Master File Entries: see list20
Suppliers: see list5
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Clinical Trials for: zolmitriptan

Determine Central 5-HT1B Receptor Occupancy of ZOMIGĀ® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Status: Completed Condition: Migraine

ZAP, US. Zomig for Appropriate for Primary Care
Status: Completed Condition: Migraine

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status: Completed Condition: Migraine

Efficacy and Tolerability of Zolmitriptan Nasal Spray
Status: Completed Condition: Migraine

Zomig - Treatment of Acute Migraine Headache in Adolescents
Status: Completed Condition: Migraine Headache; Adolescents

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Status: Completed Condition: Acute Migraine; Migraine Headache; Headache Disorders

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury
Status: Completed Condition: Spinal Cord Injuries; Muscle Spasticity

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Status: Completed Condition: Migraine

Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Status: Completed Condition: Migraine Disorders

Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy
Status: Completed Condition: Migraine Disorders

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc
TABLET, ORALLY DISINTEGRATING;ORAL202890May 15, 2013RXNo<disabled><disabled>
Teva Pharms Usa
TABLET;ORAL090861Mar 4, 2014RXNo<disabled><disabled>
SPRAY;NASAL021450Sep 30, 2003RXYes6,750,237*PED<disabled>Y<disabled>
Apotex Inc
TABLET;ORAL202078May 14, 2013RXNo<disabled><disabled>
TABLET, ORALLY DISINTEGRATING;ORAL021231Sep 17, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology